查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1828216

2025年全球卵巢癌診斷市場報告

Ovarian Cancer Diagnostics Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，卵巢癌診斷市場呈現強勁成長勢頭，市場規模從2024年的27.4億美元成長至2025年的29億美元，複合年成長率為5.7%。預測期內的成長歸因於生物標記的發現和檢驗、經陰道超音波的普及、對BRCA基因突變的認知，以及腫瘤標記研究、篩檢計畫和指南的不斷發展。

預計未來幾年卵巢癌診斷市場將強勁成長，2029年將達到38.8億美元，年複合成長率（CAGR）為7.6%。預測期內的成長可歸因於早期檢測工作、卵巢癌盛行率的上升、人工智慧 (AI) 的整合、個人化醫療方法、新型生物標記的出現以及基因組和蛋白質組學分析。預測期內的主要趨勢包括用於早期檢測的生物感測器技術、數位病理整合、成像模式的創新、成像技術的改進以及病理診斷技術的進步。

卵巢癌診斷涵蓋一系列旨在檢測和診斷卵巢癌的方法和程序。這包括症狀評估、身體檢查以及各種診斷測試的應用。卵巢癌是一種影響卵巢（女性生殖器官）的惡性腫瘤，需要準確的診斷方法才能及時有效地介入。

卵巢癌診斷產品主要分為儀器、套件及試劑。儀器在醫學診斷中起著至關重要的作用，包括超音波和MRI等影像設備、使用CA-125和HE4等標記物的血液檢測，以及切片檢查和腹腔鏡檢查等組織採樣技術。切片檢查、血液檢測和成像等各種診斷方法用於識別特定類型的卵巢癌，例如上皮細胞腫瘤、生殖細胞腫瘤和基質細胞腫瘤。這些診斷工具被不同的最終用戶使用，包括癌症診斷中心、醫院實驗室和研究機構。全面的診斷技術有助於準確、有針對性地識別卵巢癌亞型，從而促進個人化治療方法。

2025年春季美國關稅的突然上調及其引發的貿易摩擦對醫療設備行業產生了重大影響，尤其對用於診斷影像設備的進口零件、手術用不銹鋼和一次性塑膠製品產生了重大影響。由於醫院和診所抵制漲價，製造商面臨利潤壓力。監管挑戰使情況更加複雜，因為由於關稅而更換供應商通常需要重新認證醫療設備，導致市場進入延遲。為此，企業正在透過雙重採購關鍵零件、增加標準化產品的國內生產以及加快尋找更具成本效益的材料來降低風險。

本研究報告是商業研究公司 (The Business Research Company) 新報告系列的一部分，該系列提供卵巢癌診斷市場統計數據，例如全球市場規模、區域佔有率、卵巢癌診斷市場佔有率競爭對手、詳細的卵巢癌診斷細分市場、市場趨勢和商業機會，以及您在卵巢癌診斷行業取得成功所需的數據。本卵巢卵巢診斷市場研究報告對該行業的現狀和未來趨勢進行了詳細分析，為您提供所需的一切全面觀點。

未來五年7.6%的預測成長率，較我們先前對該市場的預測略有下降0.1%。下降主要源自於美國與其他國家之間關稅的影響。這種影響可能會直接影響美國，導致專用抗體試劑和微流體晶片（主要進口自瑞士和新加坡）的供應鏈中斷，從而可能推遲先進的癌症篩檢檢測。由於互惠關稅以及貿易緊張局勢和限制措施加劇對全球經濟和貿易的負面影響，這種影響也將更加廣泛。

卵巢癌盛行率的不斷上升預計將推動未來卵巢癌診斷市場的成長。卵巢癌是一種發生於卵巢的惡性腫瘤，卵巢是負責產生卵子和荷爾蒙的女性生殖器官。卵巢癌盛行率的上升歸因於預期壽命的延長、生育年齡的延遲以及生活方式的改變等因素。有效的卵巢癌診斷方法有助於早期發現和早期療育，最終實現及時治療並改善患者預後，在降低卵巢癌發生率方面發揮關鍵作用。例如，2022年，致力於意識提升對卵巢癌女性認知的加拿大組織世界卵巢癌組織報告稱，到2050年，全球女性卵巢癌發病率預計將增加55%以上，達到約503,448例。此外，卵巢癌的年死亡率預計將上升至350,956人，與2022年相比增加近70%。因此，卵巢癌盛行率的上升正在推動卵巢癌診斷市場的擴張。

婦科癌症患者數量的不斷成長預計將進一步推動卵巢癌診斷市場的成長。婦科癌症涵蓋所有起源於女性生殖器官的癌症。卵巢癌診斷對於該疾病的治療和管理、預防復發以及透過各種治療改善患者預後至關重要。例如，2024年2月，美國國家醫學圖書館（美國生物醫學圖書館和國家醫療專業人員資源中心）報告稱，婦科癌症的超額死亡率從2021年的3.30%上升到2022年的8.42%。因此，婦科癌症的高發生率正在推動卵巢癌診斷市場的成長。

卵巢癌診斷市場正經歷先進診斷技術日益普及的顯著趨勢。該市場中的企業正積極擁抱這些技術，將其視為保持競爭力的策略工具。總部位於瑞士的製藥保健公司霍夫曼-羅氏（Hoffmann-La Roche）就是一個例子。 2022年11月，該公司的VENTANA FOLR1 (FOLR1-2.1) RxDx檢測試劑盒獲得美國食品藥物管理局（FDA）核准。這款基於免疫組織化學 (IHC) 的突破性伴隨診斷檢測套組可識別符合處方藥ELAHERE資格的卵巢癌患者。此次核准代表了診斷能力的重大進步，為改善疾病管理和患者預後提供了重要的見解和詳細的臨床資訊。

卵巢癌診斷市場包括提供基因檢測、手術、化療、標靶治療和荷爾蒙療法的營業單位所獲得的收益。市場規模還包括服務供應商銷售的或包含在其服務產品中的相關產品的價值。卵巢癌診斷市場還包括超音波機器、切片檢查工具、基因檢測套組、免疫組織化學 (IHC)套件和卵巢癌生物標記組的銷售。該市場的價值是「工廠門口」價值；即產品製造商或創造者向其他營業單位（包括下游製造商、批發商、經銷商和零售商）或直接向最終客戶銷售的產品價值。該市場中的產品價值還包括產品創造者銷售的任何相關服務。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通膨、地緣政治、貿易戰和關稅，以及新冠疫情和復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球卵巢癌診斷：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
  • 最終用途產業分析
  • 全球卵巢癌診斷市場：成長率分析
  • 全球卵巢癌診斷市場表現：規模與成長，2019-2024
  • 全球卵巢癌診斷市場預測：規模與成長，2024-2029，2034
  • 全球卵巢癌診斷：總目標市場（TAM）

第6章 市場細分

  • 全球卵巢癌診斷市場（依產品類型、績效及預測），2019-2024 年、2024-2029 年、2034 年
  • 裝置
  • 套件
  • 試劑
  • 全球卵巢癌診斷市場（按診斷類型、表現和預測），2019-2024 年、2024-2029 年、2034 年
  • 切片檢查
  • 血液檢查
  • 影像學
  • 其他
  • 全球卵巢癌診斷市場（按癌症類型、表現和預測），2019-2024 年、2024-2029 年、2034 年
  • 上皮性腫瘤
  • 生殖細胞腫瘤
  • 基質細胞腫瘤
  • 其他
  • 全球卵巢癌診斷市場（按最終用戶、績效和預測），2019-2024 年、2024-2029 年、2034 年
  • 癌症診斷中心
  • 醫院檢查室
  • 研究所
  • 全球卵巢癌診斷市場：設備細分、類型、性能和預測，2019-2024 年、2024-2029 年、2034 年
  • 影像系統
  • 切片檢查裝置
  • 分子診斷設備
  • 全球卵巢癌診斷市場：套件細分、類型、效能及預測（2019-2024、2024-2029、2034）
  • 診斷檢測套組
  • 篩檢套件
  • 全球卵巢癌診斷市場：試劑細分、類型、效能及預測（2019-2024、2024-2029、2034）
  • 抗體
  • 酵素
  • 檢測試劑

第7章 區域和國家分析

  • 全球卵巢癌診斷市場：依地區、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 全球卵巢癌診斷市場：依國家、表現及預測，2019-2024 年、2024-2029 年、2034 年

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章：澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章 西歐市場

第16章英國市場

第17章：德國市場

第18章：法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章：競爭格局與公司概況

  • 卵巢癌診斷市場：競爭格局
  • 卵巢癌診斷市場：公司簡介
    • F. Hoffmann-La Roche Ltd.
    • Thermo Fisher Scientific Inc.
    • AstraZeneca plc
    • Abbott Laboratories
    • GlaxoSmithKline plc

第31章：其他領先和創新企業

  • Eli Lilly and Company
  • GE HealthCare Technologies Inc.
  • Quest Diagnostics Incorporated
  • Agilent Technologies Inc.
  • Hologic Inc.
  • Illumina Inc.
  • PerkinElmer Inc.
  • Sysmex Corporation
  • Bio-rad Laboratories Inc.
  • Qiagen NV
  • Natera Inc.
  • Myriad Genetics Inc.
  • ArcherDX Inc.
  • Invitae Corporation
  • Guardant Health

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第35章：市場潛力大的國家與策略

  • 2029年卵巢癌診斷市場：提供新機會的國家
  • 2029年卵巢癌診斷市場：細分市場帶來新機會
  • 卵巢癌診斷市場2029年：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第36章 附錄

簡介目錄
Product Code: r25178u

Ovarian cancer diagnostics encompass a range of methods and procedures aimed at detecting and diagnosing ovarian cancer. This involves the evaluation of symptoms, physical examinations, and the application of various diagnostic tests. Ovarian cancer, a malignancy affecting the ovaries within the female reproductive system, necessitates accurate diagnostic approaches for timely and effective intervention.

The primary categories of ovarian cancer diagnostic products comprise instruments, kits, and reagents. Instruments play a pivotal role in medical diagnostics, encompassing imaging devices such as ultrasound and MRI, blood tests utilizing markers such as CA-125 and HE4, as well as tissue sampling techniques including biopsy and laparoscopy. Various diagnostic methods, such as biopsy, blood tests, imaging, and others, are deployed to identify specific types of ovarian cancer, including epithelial tumors, germ cell tumors, stromal cell tumors, among others. These diagnostic tools find application across diverse end-users, including cancer diagnostic centers, hospital laboratories, and research institutes. The comprehensive array of diagnostic techniques contributes to accurate and targeted identification of ovarian cancer subtypes, facilitating tailored treatment approaches.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.

The ovarian cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides ovarian cancer diagnostics market statistics, including ovarian cancer diagnostics industry global market size, regional shares, competitors with a ovarian cancer diagnostics market share, detailed ovarian cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the ovarian cancer diagnostics industry. This ovarian cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ovarian cancer diagnostics market size has grown strongly in recent years. It will grow from $2.74 billion in 2024 to $2.9 billion in 2025 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to growth in biomarker discovery and validation, transvaginal ultrasound adoption, BRCA gene mutations awareness, research on tumor markers, screening programs and guidelines.

The ovarian cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $3.88 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to early detection initiatives, increasing incidence of ovarian cancer, integration of artificial intelligence (AI), personalized medicine approaches, emergence of novel biomarkers, and genomic and proteomic profiling. Major trends in the forecast period include biosensor technologies for early detection, digital pathology integration, innovations in imaging modalities, improved imaging technologies, and advancements in pathology techniques.

The forecast of 7.6% growth over the next five years indicates a slight reduction of 0.1% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through supply chain disruptions for specialized antibody reagents and microfluidic chips, key imports from Switzerland and Singapore, potentially delaying advanced cancer screening tests.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing prevalence of ovarian cancer is projected to boost the growth of the ovarian cancer diagnostics market in the future. Ovarian cancer is a malignant tumor that originates in the ovaries, which are the female reproductive organs responsible for producing eggs and hormones. This rise can be attributed to factors such as longer life expectancies, delayed childbearing, and lifestyle changes. Effective ovarian cancer diagnostics play a crucial role in reducing the incidence of the disease by facilitating early detection and intervention, ultimately leading to timely treatment and improved patient outcomes. For example, in 2022, the World Ovarian Cancer, a Canadian organization dedicated to raising awareness for women affected by ovarian cancer globally, reported that by 2050, the global incidence of ovarian cancer among women is anticipated to increase by over 55%, reaching around 503,448 cases. Additionally, the annual mortality rate from ovarian cancer is expected to rise to 350,956, representing an almost 70% increase compared to 2022. Therefore, the growing prevalence of ovarian cancer is driving the expansion of the ovarian cancer diagnostics market.

The rise in gynecological cancer cases is expected to further accelerate the growth of the ovarian cancer diagnostics market. Gynecologic cancer encompasses any cancer that begins in a woman's reproductive organs. Ovarian cancer diagnostics are essential for treating and managing the disease, preventing recurrence, and enhancing patient outcomes through various therapies. For instance, in February 2024, the National Library of Medicine, a US-based biomedical library and national resource for health professionals, reported that excess mortality rates for gynecological cancer increased from 3.30% in 2021 to 8.42% in 2022. Consequently, the high prevalence of gynecological cancer is propelling the growth of the ovarian cancer diagnostics market.

The ovarian cancer diagnostics market is witnessing a notable trend with the increasing adoption of advanced diagnostic technology. Companies in this market are actively incorporating advanced diagnostic technologies as a strategic move to maintain their competitive positions. An illustrative example is Hoffmann-La Roche AG, a pharmaceutical and healthcare company based in Switzerland. In November 2022, the company secured FDA approval for the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay. This groundbreaking immunohistochemistry (IHC)-based companion diagnostic test kit identifies ovarian cancer patients eligible for the prescription medication ELAHERE. The approval signifies a significant advancement in diagnostic capabilities, providing critical insights and detailed clinical information for improved disease management and patient outcomes.

Major players in the ovarian cancer diagnostics market are actively engaging in partnerships to foster product development and fortify their market positions. Collaborative efforts in this sector contribute to enhanced research, development, and commercialization by leveraging the combined expertise, resources, and networks of multiple entities. For instance, in August 2023, ImmunoGen Inc., a US-based biotechnology company, joined forces with Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company. This partnership focuses on the development and commercialization of ELAHERE (mirvetuximab soravtansine-gynx) in Japan. ImmunoGen stands to benefit from upfront and milestone payments, along with double-digit royalties, while Takeda gains exclusive rights to develop and commercialize ELAHERE in Japan. This collaboration addresses an unmet need for individuals with platinum-resistant ovarian cancer, showcasing a shared commitment to advancing cancer treatment options on a global scale.

In September 2022, GENinCode PLC, a biotechnology company based in the UK specializing in genetic testing for assessing the risk of cardiovascular diseases, successfully completed the acquisition of Abcodia for a sum of $1.25 million. This strategic acquisition marks a significant expansion, diversification, and reinforcement of GENinCode's technological capabilities. The addition of Abcodia's advanced algorithm technology for the risk assessment of ovarian cancer (ROCA) enhances GENinCode's portfolio, particularly in the domain of early detection of ovarian cancer. Abcodia, also based in the UK, is recognized for its expertise in manufacturing biomarkers designed for the early identification of ovarian cancer. This acquisition underscores GENinCode's commitment to advancing its technology and expanding its offerings, positioning the company as a more comprehensive player in the field of genetic testing and diagnostics.

Major companies operating in the ovarian cancer diagnostics market include F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, GE HealthCare Technologies Inc., Quest Diagnostics Incorporated, Agilent Technologies Inc., Hologic Inc., Illumina Inc., PerkinElmer Inc., Sysmex Corporation, Bio-rad Laboratories Inc., Qiagen N.V., Natera Inc., Myriad Genetics Inc., ArcherDX Inc., Invitae Corporation, Guardant Health, Luminex Corporation, NanoString Technologies Inc., Siemens Healthcare Private Limited, Menarini Silicon Biosystems S.p.A., Precipio Inc., Angle plc

North America was the largest region in the ovarian cancer diagnostic market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ovarian cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ovarian cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ovarian cancer diagnostic market includes revenues earned by entities by providing genetic testing, surgery, chemotherapy, target therapy, and hormone therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The ovarian cancer diagnostic market also includes sales of ultrasound machines, biopsy tools, genetic testing kits, immunohistochemistry (IHC) kits, and ovarian cancer biomarker panels. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ovarian Cancer Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ovarian cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ovarian cancer diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The ovarian cancer diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product Type: Instruments; Kits; Reagents
  • 2) By Diagnosis Type: Biopsy; Blood Test; Imaging; Other Diagnosis Types
  • 3) By Cancer Type: Epithelial Tumor; Germ Cell Tumor; Stromal Cell Tumor; Other Cancer Types
  • 4) By End User: Cancer Diagnostic Centers; Hospital Laboratories; Research Institutes
  • Subsegments:
  • 1) By Instruments: Imaging Systems; Biopsy Devices; Molecular Diagnostic Instruments
  • 2) By Kits: Diagnostic Test Kits; Screening Kits
  • 3) By Reagents: Antibodies; Enzymes; Assay Reagents
  • Companies Mentioned: F. Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; AstraZeneca plc; Abbott Laboratories; GlaxoSmithKline plc; Eli Lilly and Company; GE HealthCare Technologies Inc.; Quest Diagnostics Incorporated; Agilent Technologies Inc.; Hologic Inc.; Illumina Inc.; PerkinElmer Inc.; Sysmex Corporation; Bio-rad Laboratories Inc.; Qiagen N.V.; Natera Inc.; Myriad Genetics Inc.; ArcherDX Inc.; Invitae Corporation; Guardant Health; Luminex Corporation; NanoString Technologies Inc.; Siemens Healthcare Private Limited; Menarini Silicon Biosystems S.p.A.; Precipio Inc.; Angle plc
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Ovarian Cancer Diagnostics Market Characteristics

3. Ovarian Cancer Diagnostics Market Trends And Strategies

4. Ovarian Cancer Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Ovarian Cancer Diagnostics Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Ovarian Cancer Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Ovarian Cancer Diagnostics Market Growth Rate Analysis
  • 5.4. Global Ovarian Cancer Diagnostics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Ovarian Cancer Diagnostics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Ovarian Cancer Diagnostics Total Addressable Market (TAM)

6. Ovarian Cancer Diagnostics Market Segmentation

  • 6.1. Global Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Instruments
  • Kits
  • Reagents
  • 6.2. Global Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Biopsy
  • Blood Test
  • Imaging
  • Other Diagnosis Types
  • 6.3. Global Ovarian Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Epithelial Tumor
  • Germ Cell Tumor
  • Stromal Cell Tumor
  • Other Cancer Types
  • 6.4. Global Ovarian Cancer Diagnostics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Cancer Diagnostic Centers
  • Hospital Laboratories
  • Research Institutes
  • 6.5. Global Ovarian Cancer Diagnostics Market, Sub-Segmentation Of Instruments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Imaging Systems
  • Biopsy Devices
  • Molecular Diagnostic Instruments
  • 6.6. Global Ovarian Cancer Diagnostics Market, Sub-Segmentation Of Kits, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Diagnostic Test Kits
  • Screening Kits
  • 6.7. Global Ovarian Cancer Diagnostics Market, Sub-Segmentation Of Reagents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Antibodies
  • Enzymes
  • Assay Reagents

7. Ovarian Cancer Diagnostics Market Regional And Country Analysis

  • 7.1. Global Ovarian Cancer Diagnostics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Ovarian Cancer Diagnostics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Ovarian Cancer Diagnostics Market

  • 8.1. Asia-Pacific Ovarian Cancer Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Ovarian Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Ovarian Cancer Diagnostics Market

  • 9.1. China Ovarian Cancer Diagnostics Market Overview
  • 9.2. China Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Ovarian Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Ovarian Cancer Diagnostics Market

  • 10.1. India Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Ovarian Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Ovarian Cancer Diagnostics Market

  • 11.1. Japan Ovarian Cancer Diagnostics Market Overview
  • 11.2. Japan Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Ovarian Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Ovarian Cancer Diagnostics Market

  • 12.1. Australia Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Ovarian Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Ovarian Cancer Diagnostics Market

  • 13.1. Indonesia Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Ovarian Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Ovarian Cancer Diagnostics Market

  • 14.1. South Korea Ovarian Cancer Diagnostics Market Overview
  • 14.2. South Korea Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Ovarian Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Ovarian Cancer Diagnostics Market

  • 15.1. Western Europe Ovarian Cancer Diagnostics Market Overview
  • 15.2. Western Europe Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Ovarian Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Ovarian Cancer Diagnostics Market

  • 16.1. UK Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Ovarian Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Ovarian Cancer Diagnostics Market

  • 17.1. Germany Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Ovarian Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Ovarian Cancer Diagnostics Market

  • 18.1. France Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Ovarian Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Ovarian Cancer Diagnostics Market

  • 19.1. Italy Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Ovarian Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Ovarian Cancer Diagnostics Market

  • 20.1. Spain Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Ovarian Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Ovarian Cancer Diagnostics Market

  • 21.1. Eastern Europe Ovarian Cancer Diagnostics Market Overview
  • 21.2. Eastern Europe Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Ovarian Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Ovarian Cancer Diagnostics Market

  • 22.1. Russia Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Ovarian Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Ovarian Cancer Diagnostics Market

  • 23.1. North America Ovarian Cancer Diagnostics Market Overview
  • 23.2. North America Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Ovarian Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Ovarian Cancer Diagnostics Market

  • 24.1. USA Ovarian Cancer Diagnostics Market Overview
  • 24.2. USA Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Ovarian Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Ovarian Cancer Diagnostics Market

  • 25.1. Canada Ovarian Cancer Diagnostics Market Overview
  • 25.2. Canada Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Ovarian Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Ovarian Cancer Diagnostics Market

  • 26.1. South America Ovarian Cancer Diagnostics Market Overview
  • 26.2. South America Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Ovarian Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Ovarian Cancer Diagnostics Market

  • 27.1. Brazil Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Ovarian Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Ovarian Cancer Diagnostics Market

  • 28.1. Middle East Ovarian Cancer Diagnostics Market Overview
  • 28.2. Middle East Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Ovarian Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Ovarian Cancer Diagnostics Market

  • 29.1. Africa Ovarian Cancer Diagnostics Market Overview
  • 29.2. Africa Ovarian Cancer Diagnostics Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Ovarian Cancer Diagnostics Market, Segmentation By Diagnosis Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Ovarian Cancer Diagnostics Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Ovarian Cancer Diagnostics Market Competitive Landscape And Company Profiles

  • 30.1. Ovarian Cancer Diagnostics Market Competitive Landscape
  • 30.2. Ovarian Cancer Diagnostics Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. Ovarian Cancer Diagnostics Market Other Major And Innovative Companies

  • 31.1. Eli Lilly and Company
  • 31.2. GE HealthCare Technologies Inc.
  • 31.3. Quest Diagnostics Incorporated
  • 31.4. Agilent Technologies Inc.
  • 31.5. Hologic Inc.
  • 31.6. Illumina Inc.
  • 31.7. PerkinElmer Inc.
  • 31.8. Sysmex Corporation
  • 31.9. Bio-rad Laboratories Inc.
  • 31.10. Qiagen N.V.
  • 31.11. Natera Inc.
  • 31.12. Myriad Genetics Inc.
  • 31.13. ArcherDX Inc.
  • 31.14. Invitae Corporation
  • 31.15. Guardant Health

32. Global Ovarian Cancer Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Ovarian Cancer Diagnostics Market

34. Recent Developments In The Ovarian Cancer Diagnostics Market

35. Ovarian Cancer Diagnostics Market High Potential Countries, Segments and Strategies

  • 35.1 Ovarian Cancer Diagnostics Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Ovarian Cancer Diagnostics Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Ovarian Cancer Diagnostics Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer